Received Mar 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 2 | Y014182 | — |
no side effects or symptoms reported. No Additional AE/ No PQC.; patient received their second dose of VARIVAX too early at 3 years and 8 months old; This spontaneous report was received from a certified medical assistant and refers to a 3 years and 8 months female patient. No information regarding the patient's medical history, concurrent conditions, concomitant medications, drug reactions or allergies was provided. On an unknown date approximately in 2022 (reported as at approximately 12 months of age), the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck)(VARIVAX) (dose, lot #, expiration date, route and site of administration were not reported) reconstituted with sterile diluent (lot # and expiration date were not reported) for prophylaxis. On 29-JAN-2025, at the age of 3 years and 8 months, the patient was vaccinated too early with the second dose of Varicella Virus Vaccine Live (Oka-Merck)(VARIVAX) 0.5 ml, lot # Y014182 was confirmed to be valid, expiration date 20-AUG-2026 (route and site of administration were not reported) reconstituted with sterile diluent (lot # and expiration date were not reported) for prophylaxis.
sterile diluent